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Introduction: The aim of this study was to examine the prevalence and functional effects of antibodies directed
against Factor (F)Xa and other serine proteases (SP) in patients with antiphospholipid syndrome (APS).
Methods: Serum from patients with APS (n = 59), systemic lupus erythematosus (SLE; n = 106), other autoimmune
rheumatic disease (ARD; n = 63) and 40 healthy controls (HC) were tested for IgG activity against thrombin (Thr),
FXa, FVIIa, phosphatidylserine (PS)/FXa and antithrombin (AT)-III by enzyme-linked immunosorbent assay (ELISA).
Anti-FXa positive IgG were purified to measure their avidity by chaotropic ELISA and functional effects upon clotting
time (FXa-ACT) and FXa enzymatic activity (± AT-III).
Results: Anti-FXa IgG were found in patients with SLE (49.1%) and APS (33.9%) (P <0.05) but not in ARD controls
and HC. In contrast, anti-Thr and anti-PS/FXa IgG were identified in other ARD and anti-FVIIa IgG were low in all
groups. The avidity of APS-IgG to FXa was significantly higher than SLE-IgG (P <0.05). Greatest prolongation of
FXa-ACT was observed with APS-IgG and greatest inhibitory effect upon FXa enzymatic activity was found with
APS-IgG followed by SLE-IgG compared to HC-IgG. ATIII inhibition of FXa was significantly reduced by APS-IgG
compared with HC and SLE (P <0.05) and did not correlate with binding to AT-III.
Conclusion: APS anti-FXa IgG have higher avidity to FXa and greater effects upon the enzymatic and coagulant
activity of FXa compared with SLE anti-FXa IgG. Further studies of anti-FXa antibodies in APS, SLE and other
non-autoimmune thrombotic disease cohorts are now required to evaluate whether targeting FXa with selective
inhibitors in patients bearing anti-FXa antibodies may be an effective treatment strategy.Introduction
APS is a common cause of acquired vascular thrombosis
[1] and recurrent miscarriage [2]. Its diagnosis is contin-
gent upon the identification of antiphospholipid anti-
bodies (aPL) by anticardiolipin (aCL), anti-β2-glycoprotein
I (anti-β2GPI) and/or lupus anticoagulant (LA) tests.
These aPL interact with a variety of haemostasis proteins
as well as a number of target cells including monocytes,
endothelial cells (EC) and trophoblasts, leading to the re-
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stated.intracellular signalling pathways [3]. Given that vascular
thrombosis is a major manifestation of the APS, much
interest has focussed upon the interactions of aPL with
coagulation factors.
Proteins such as thrombin, activated protein C (APC),
plasmin, tissue plasminogen activator (tPA), activated
Factor (F) VIIa, FIXa, FXa and FXIIa all belong to the
trypsin-like serine protease (SP) family of enzymes and
are involved in the tight regulation of haemostasis [4].
Vascular injury leads to exposure of the transmembrane
receptor tissue factor (TF) to FVIIa and subsequent TF/
FVIIa complex formation that activates FX to FXa
directly and indirectly via FIXa activation. FXa subse-
quently converts prothrombin to trace amounts of Thr,
the generation of which is then propagated by activation
of FV and FVIII [5]. Thus FXa has a central position intral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and anti-inflammatory effects [6].
Numerous studies have shown interactions of mono-
clonal and polyclonal aPL with various SP. A panel of
monoclonal human aPL display cross-reactivity with SP,
binding to Thr, APC, plasmin, tPA, FIXa and FXa [7-11],
which all share amino-acid sequence homology at their
catalytic sites. Given that several monoclonal human aPL
inhibit the inactivation of procoagulant SP and functional
activities of anticoagulant/fibrinolytic SP [7,9,12,13], it has
been suggested that some aPL may recognise the catalytic
domain of SP, leading to dysregulation of haemostasis and
vascular thrombosis in APS. Previously, we have shown
that amino-acid sequence changes in the antigen bind-
ing sites of human monoclonal aPL are important in
determining their ability to bind procoagulant and anti-
coagulant/fibrinolytic SP, with binding to Thr predicting
pathogenicity in mice [14].
Other studies have identified that between 13 and 54% of
sera from patients with APS (including 20 to 50% systemic
lupus erythematosus (SLE)-associated APS) bind different
SP [9,12,15]. We found that anti-Thr IgG are significantly
elevated in patients with APS and in patients with SLE
who are aPL-positive but lacked APS (SLE/aPL+/APS-)
compared to healthy controls. Furthermore, IgG purified
from patients with APS displayed higher avidity for Thr,
and significantly inhibited antithrombin (AT)-III inactiva-
tion of Thr compared with IgG from SLE/aPL+/APS- and
healthy controls [16]. These findings are relevant to the
pathogenesis of APS, as high-avidity anti-Thr antibodies,
which prevent Thr inactivation, are more likely to promote
vascular thrombosis than low avidity anti-Thr antibodies,
which do not prevent Thr inactivation.
In this study we have examined the prevalence of different
anti-SP IgG in a large cohort with APS, SLE/APS-, as well as
in healthies and control patients with disease and found that
IgG anti-FXa positivity distinguished patients with APS and
SLE/APS- from the other control groups. Given the central
position of FXa in coagulation and inflammatory pathways
we then examined the significance of IgG-FXa interactions
and their effects upon the coagulant functions of FXa.
Methods
Reagents
Unless otherwise stated, coagulation factors were from
Haematologic Technologies, Essex Junction, Vermont,
USA. Porcine gelatin, bovine serum albumin (BSA) and
conjugated antibodies were from Sigma-Aldrich, Suffolk,
UK. Chromogenic substrates for ELISA were from KPL,
Gaithersburg, Maryland, USA.
Patients and healthy controls
Serum was obtained from 228 patients (University College
London Hospital) with APS, n = 59; SLE and no APS(SLE/APS-), n = 106; rheumatoid arthritis (RA), n = 12;
Sjögren’s syndrome (SS), n = 13; myositis (Myo), n = 23;
systemic sclerosis (SSc), n = 15; and 40 healthy controls
(HC). All patients satisfied relevant disease classification
criteria for APS [17], SLE [18], RA [19], SS [20], Myo
[21] and SSc [22]. Informed consent and full ethical ap-
proval from the local ethics board were obtained (National
Research Ethics Committee- London Hampstead, reference
number 12/LO/0373). Patients in the SLE cohort had their
disease activity recorded using the Classic British Isles
Lupus Assessment Group (BILAG) index [23]. We did not
use the BILAG 2004 index [24] as many of the samples
were obtained prior to its routine use.
Immunologic characterisation and purification of IgG
IgG was protein G-purified (Fisher Scientific, Loughborough,
UK) dialysed in PBS and the concentration determined by
spectrophotometry. Serum and purified IgG aCL and anti-
β2GPI titers were measured as previously described [14].
The presence of IgG directed against Thr; FXa; FVIIa; pro-
thrombin (PT); phosphatidylserine (PS)/FXa complex;
and AT-III was measured by ELISA. All samples were
tested in duplicate and considered positive when the
test optical density (OD) minus the background OD
exceeded the mean OD + 3 SD of HC. Results were
expressed as percentage binding of a positive control
and number and percentage of positive patients for the
relevant IgG was calculated accordingly.
Anti-Thr ELISA
Unless otherwise stated, in all ELISAs half of the plate
was coated with antigen (test side) and buffer alone to
the other half (background side); the coating step was
performed overnight at 4°C; and all other steps were at
room temperature (RT). Anti-Thr antibodies were de-
tected as described previously (16). Costar plates (Costar,
UK) were coated with 10 μg/ml human alpha-Thr in Tris-
buffered saline (TBS). Plates were blocked with TBS/0.3%
gelatin for 1 hour. Serum 1:50 in TBS/0.1% gelatin was in-
cubated for 1.5 hours at RT and bound IgG detected by
addition of alkaline phosphatase (ALP)-conjugated anti-
human IgG in TBS/0.1% gelatin for 1 hour followed by
addition of substrate and absorbance read at 405 nm.
Anti-PT ELISA
Anti-PT antibodies were detected as described previously
[25]. MaxiSorp plates (Nunc, UK) were coated with 10 μg/
ml human alpha-PT in TBS. Plates were blocked with
TBS/1% BSA for 2 hours. Serum 1:50 in TBS/1% BSA
was incubated for 1.5 hours and bound IgG detected by
addition of ALP conjugate in TBS/1% BSA for 1 hour
followed by addition of substrate and absorbance read
at 405 nm.
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Anti-FVIIa antibodies were detected by modifications of
the method of Bidot et al. [26]. MaxiSorp plates were
coated with 1.5 μg/ml recombinant human FVIIa (Novo
Nordisk) in PBS. Plates were blocked with PBS/2% BSA
for 1.5 hours at 37°C. Serum diluted in PBS/1% BSA was
incubated for 1 hour. Bound IgG was detected by addition
of 50 μl horseradish peroxidase (HRP)-conjugated goat
anti-human IgG in PBS/1% BSA for 1 hour followed by
addition of substrate and absorbance read at 450 nm.
Anti-FXa ELISA
Anti-FXa antibodies were detected according to the
method described by Yang et al. [11]. Costar plates were
coated with 5 μg/ml FXa in TBS. Plates were blocked
with 150 μl TBS/0.3% gelatin for 1.5 hours. Serum 1:50
or IgG (200 μg/ml) diluted in TBS/0.3% gelatin were
incubated for 1.5 hours. Bound IgG was detected by the
addition of HRP conjugate in TBS/0.3% gelatin for 1
hour followed by addition of substrate and absorbance
read at 450 nm.
Anti-PS/FXa ELISA
IgG against PS/FXa complexes were detected by modifi-
cation of the PS/PT method of Atsumi et al [27]. All
wells of polysorp plates (Nunc, UK) were coated with PS
(50 μg/ml) (Sigma-Aldrich, UK) in methanol:chloroform
4:1 and incubated uncovered overnight. Plates were
blocked with TBS/1% BSA/5 mM CaCl2 (TBSA-Ca) for
1 hour. FXa (5 μg/ml) in TBSA-Ca was added to the test
half of the plate and TBSA-Ca alone to the control half
for 1 hr. Serum or IgG in TBSA-Ca was incubated for 1
hr, followed by ALP conjugate for 45 minutes. Bound
IgG was detected by addition of substrate and absorb-
ance read at 405 nm.
Anti -AT-III ELISA
To detect anti-AT-III IgG, maxisorp plates were coated
with 10 μg/ml human AT-III in PBS. Plates were blocked
with PBS/4% gelatin for 2 hours. Serum or IgG in PBS/
1% gelatin were incubated for 1 hour at 37°C, followed
by HRP conjugate in PBS/1% gelatin for 1 hour at 37°C.
Bound IgG was detected by addition of substrate and ab-
sorbance read at 450 nm.
Chaotropic ELISA for determination of avidity of anti-FXa
antibodies
This ELISA was adapted from that described previously
to measure the avidity of IgG-Thr [16] and IgG-β2GPI
[28] interactions. Briefly, Costar plates were coated and
blocked as per the anti-FXa ELISA. IgG, purified from
patient sera-positive for anti-FXa (absorbance units
(AU) >mean + 3SD of HC), was diluted in TBS/0.3% gel-
atin containing increasing concentrations of NaCl (0.15M, 0.25 M, 0.35 M, 0.5 M, 1 M, 2 M, 3 M, and 4.5 M) and
incubated for 1.5 hours. Bound IgG was detected as per
the anti-FXa ELISA and avidity determined by calculating
the percentage of maximum binding (100%, at 0.15 M
NaCl) maintained with each concentration of NaCl.
Clotting assay for FXa activity
FXa-activated clotting time (ACT) was measured using a
KC4 coagulometer (Amelung, Lemgo, Germany). Equal
volumes of FXa (final concentration 3.9 nM) in PBS and
purified IgGs (final concentration 200 μg/ml) diluted in
normal human plasma (NHP) (Sekisui Diagnostics, LLC)
were mixed and incubated for 10 minutes at 37°C. Reaction
mixture was re-calcified by the addition of equal volume of
Recalmix (Hep-test clotting assay, Sekisui Diagnostics,
LLC) containing CaCl2, PL, FV and fibrinogen. The time
it took for the mixture to clot (in seconds) was recorded
and a normal reference range was determined by incubat-
ing FXa (0.12 to 250 nM) with only NHP.
Functional assay for FXa activity and AT-III inactivation
of FXa
The effects of anti-FXa IgG on FXa activity were studied
in 0.1 M Tris, 0.1 M CaCl2 and 1 mg/ml BSA (pH7.8)
buffer at RT. Briefly, human FXa (final concentration
2 nM) was mixed with IgG (final concentration 200 μg/
ml) and incubated for 10 minutes at 37°C. Subsequently,
FXa chromogenic substrate S-2765 (Chromogenix; Dia-
Pharma) was added, and generation of P-nitroaniline
was monitored at 405 nm. The standard curve was gen-
erated by 1:1 mixing FXa with PBS, in which the IgGs
were diluted. The activity of FXa was determined based
on the rate of hydrolysis of S-2765 from the linear range
of absorbance at 405 nm over time. Results were expressed
as % inhibition of IgG with FXa compared to FXa alone.
To examine whether APS and SLE IgG have a differential
inhibitory effect on FXa activity, equal amounts of
IgG from different APS and SLE samples with similar
FXa binding were mixed (to a final concentration of
200 μg/ml).
The effects of FXa-reactive IgG on FXa inactivation by
AT-III were studied in the presence of AT-III and hep-
arin, modified from Bock et al. [29]. Human AT-III was
used at a concentration that was 10 times that of human
FXa. Assay buffer was the same as FXa activity assay buf-
fer. Briefly, FXa (final concentration 2 nM) was incubated
with IgG (final concentration 200 μg/ml) for 10 minutes
at 37°C. AT-III (final concentration 20 nM) in assay buffer
containing heparin (0.05 IU/ml) was added, followed im-
mediately by the addition of S-2765 (660 μM) and OD
measured at 405 nm. The percentage of FXa inactivation
by AT-III was calculated as:
(1 - (residual FXa activity with AT-III)/(initial FXa ac-
tivity without AT-III)) × 100%.
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Data analysis was performed using GraphPad Prism. Nor-
mality of distribution was assessed using the Kolmogorov-
Smirnov test. Differences in antibody titers between patient
groups were compared by one-way analysis of variance
(ANOVA), followed by Tukey honest significant differ-
ence (HSD) post hoc analysis. Frequencies of anti-SP
antibodies in patient groups were compared by non-
parametric chi-square test. The association of anti-FXa
antibody titers with aCL, anti-β2GPI, and AT-III binding
with inhibition of AT-III inactivation were assessed
using Spearman’s rank correlation coefficient. Differences
between the APS-patient and SLE-patient groups in the
avidity of anti-FXa were ascertained by two-tailed t-test.
The effects of polyclonal anti-FXa from patients with APS,
SLE, and HC on FXa activity, AT-III-mediated inactivation
of FXa and on FXa-activated clotting time were com-
pared using the Kruskal-Wallis test followed by the
Mann-Whitney test.Results
Characteristics of subjects studied
The characteristics and SP binding data of patients with
APS and SLE, and HC are shown in Table 1. Of patients
with APS, 34 had primary APS and 25 had SLE/APS; 46
patients had thrombotic APS (31 vascular thrombosis (VT)Table 1 Clinical and laboratory features of patients with
APS and SLE, and healthy controls
Diagnosis APS
(n = 59)
SLE/APL+
(n = 60)
SLE/APL-
(n = 46)
HC
(n = 40)
Age, mean, years ± SD 46 ± 12 37 ± 11 36 ± 13 31 ± 8
Sex, male/female, n 10/49 1/59 6/40 19/21
VT only, n (%) 31 (52) 5 (8) 10 (21) 0
PM only, n (%) 13 (22) 6 (10)* 10 (25)* 0
VT + PM, n (%) 12 (20) 1 (2)* 3 (7.5)* 0
CAPS, n (%) 3 (5) 0 0 0
Other ARD, n (%) SLE 25 (42) 0 0 0
aCL, mean GPL units 59.7 15.2 13 9
Anti-β2GPI, mean AU 35,5 22 4 3
LA, n (%) 46 (78) 31 (51.7) 0 0
Anti-Thr+, n (%) 21 (35.6) 36 (60) 23 (50) 2 (5)
Anti-FVIIa+, n (%) 5 (8.5) 7 (11.7) 9 (19.6) 2 (5)
Anti-FXa+, n (%) 20 (33.9) 29 (48.3) 23 (50) 0
Anti-PS/Xa+, n (%) 8 (13.6) 20 (33.3) 15 (32.6) 1 (2.5)
*Non-APS miscarriages. Anti-β2GPI, anti- β2-glycoprotein I; aCL, anticardiolipin
antibody; APS, antiphospholipid syndrome; aPL, antiphospholipid antibody;
ARD, autoimmune rheumatic disease; AU, arbitrary units; CAPS, catastrophic
antiphospholipid syndrome; FD, fetal death; FVIIa, factor VIIa; FXa, factor Xa;
GPL, IgG phospholipid; HC, healthy control; LA, lupus anticoagulant; Myo,
myositis; RA, rheumatoid arthritis; PM, pregnancy morbidity; PS, phosphatidylserine;
SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic
sclerosis; Thr, thrombin; VT, vascular thrombosis.only, 12 vascular thrombosis and pregnancy morbidity
(PM) and 3 catastrophic APS) and 13 pregnancy mor-
bidity only. Of the 106 patients with SLE and no APS
(SLE/APS-), 60 were aPL-positive (SLE/aPL+) and 46
aPL-negative (SLE/aPL-). In the APS group, there were
31 patients on warfarin, 16 on aspirin, 8 on corticoste-
roids and 19 on immunosuppressive drugs.
In RA, SS, Myo and SSc control groups, there were
only three patients with RA and one with SS who had
vascular thrombosis. PM data for these patients were
not available. They were all negative for aCL (mean IgG
phospholipid units (GPLU) 6.76 for RA, 4.68 for SS, 4.46
for Myo and 6.38 for SSc) and did not have APS. The
mean age was 48 ± 12 in RA, 59 ± 17 in SS, 49 ± 11 in
Myo and 51 ± 17 in SSc, with male/female ratios 4/8, 0/
13, 9/14 and 0/15, respectively.
Detection of anti-SP antibodies in patients with APS
and SLE
We examined patient and HC sera for the presence of
IgG anti-SP antibodies. Figure 1A shows IgG anti-SP ac-
tivity in all groups. Anti-FXa antibody positivity (that is,
activity > mean + 3 SD of HC) was only found in patients
with SLE/APS- (n = 52, 49.1%) and APS (n = 20, 33.9%).
No HC, or patients with SS or Myo, and only one patient
with RA (8.3%) and one with SSc (8.3%) were positive for
anti-FXa (P <0.05 for comparison between all groups).
IgG anti-FXa positivity did not differ significantly between
SLE and APS samples.
IgG anti-Thr antibody positivity was also found in pa-
tients with APS (n = 21, 35.6%) and SLE/APS- (n = 59,
55.7%) more frequently than in HC (n = 2, 5%, P <0.05)
but was also seen in patients with other ARD-RA (n = 3,
25%), SS (n = 5, 38.5%), Myo (n = 10, 43.5%) and SSc (n =
5, 33.3%) at frequencies that were not significantly differ-
ent compared with APS. IgG anti-PS/FXa positivity was
found more frequently (P <0.05) in patients with the SLE/
APS- (n = 35, 33%) compared with APS (n = 8, 13.6%),
Myo (n = 1, 4.3%), SSc (n = 0) and HC (n = 0) groups. IgG
anti-FVIIa levels were low in all groups with no difference
between any disease group and HC.
IgG anti-PT was also tested in the HC, APS and SLE
samples to determine whether it was a surrogate for Thr
binding. Both the SLE and APS groups had significantly
higher prevalence of anti-PT IgG positivity compared
with HC but there was only a weak positive correlation
with anti-Thr IgG activity (r = 0.184, P = 0.024).
Within the APS group there was no significant differ-
ence in positivity for any anti-SP antibody between pa-
tients with and without SLE or between patients with VT
and those with PM. Within the SLE/APS- group there
was no difference in positivity for any anti-SP between
aPL+ and aPL- subjects. There was also no association be-
tween positivity for any anti-SP and SLE disease activity.
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Figure 1 Anti-serum protease (SP) binding in disease and control groups. (A) Activities of anti-SP IgG in all groups. Results (y-axes) were
expressed as percentage binding of a positive control. Bars represent mean ± SEM (standard error of mean) (B) Correlation of anti-factor Xa
(FXa) IgG activity with APLA IgG (aCL IgG and anti-β2GPI IgG) activity. Experiments were performed in duplicate for each sample. Results are
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with aPL IgG level (Figure 1B shows this finding for FXa).
Avidity of anti-FXa antibodies in patients with APS and SLE
To determine possible differences in the avidity of anti-
FXa between APS and SLE/APS-, we examined the bind-
ing of purified IgG (from 10 sera from each of these two
groups) to FXa under chaotropic conditions. Samples from
each group were selected for their similar levels of anti-
FXa binding in direct ELISA. We demonstrated that the
mean residual binding of polyclonal IgG to FXa was signifi-
cantly higher in samples from patients with APS compared
to SLE/APS- below 2 M NaCl (Figure 2). The mean re-
sidual binding in the APS compared with SLE/APS- groupwas 41% versus 30% at 0.25 M NaCl (P <0.05); 36% ver-
sus 25% at 0.35 M NaCl (P <0.001); 30% versus 18% at
0.5 M NaCl (P <0.001); and 23% versus 14% at 1 M
NaCl (P <0.001).
Functional effects of anti-FXa IgG on global coagulation
and FXa activity
To investigate the functional significance of the FXa re-
active IgG we examined the effects of IgG purified from
all anti-FXa-positive patients with APS (n = 16) and SLE
(n = 15) as well as anti-FXa-negative IgG from HC (n = 9)
upon FXa activity. First, we measured the effects of IgG
diluted in NHP upon FXa ACT. Figure 3A shows that the
FXa-induced clotting time was prolonged in the presence
Figure 2 Avidity of IgG anti-factor Xa (FXa) antibodies in
antiphospholipid syndrome (APS) and systemic lupus
erythematosus (SLE)/APS-negative (APS-) groups. Percentage of
maximum binding to FXa with NaCl at all concentrations tested.
Bars represent mean ± standard error of the mean (SEM); **P <0.001,
*P <0.05. Experiments were performed in duplicate for each sample.
Results are representative of at least three independent experiments.
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IgG at 63.6 ± 2.7 seconds compared with 26.8 ± 0.6 sec-
onds for HC IgG. These differences were statistically
significant (P <0.0001 for APS versus HC, P <0.0001 for
SLE versus HC, and P = 0.04 for APS versus SLE).
We then measured the specific effect of the anti-FXa
reactive IgG on the enzymatic activity of FXa in a chromo-
genic substrate assay (Figure 3B). The greatest inhibition of
FXa activity was observed with APS-IgG inhibition 9.7 ±
0.89% (mean ± SEM), followed by SLE-IgG (inhibition
7.07 ± 1.28%) whereas HC-IgG gave inhibition of only
2.58 ± 0.6%. These differences were statistically signifi-
cant; P <0.0001 for APS versus HC, P = 0.0002 for SLE
versus HC, and P = 0.0008 for APS versus SLE.Detection of the possible additive effect of APS and
SLE samples
To assess whether APS and SLE/APS- IgG may be bind-
ing to different epitopes on the active site of FXa, we se-
lected different APS (n = 5) and SLE/APS- (n = 5) IgG
on the basis of similar FXa binding and examined their
individual and combined effects (at a final concentration
of 200 μg/ml) upon FXa enzymatic activity. We hypothe-
sised that if APS and SLE/APS- IgG inhibited FXa on
their own but were binding to different epitopes on the
active site of FXa then an appreciable increase in inhib-
ition of FXa activity would be observed with the mixed
APS/SLE IgG preparations compared with individual
APS or SLE samples. This additive effect however, was
only observed in one of the five paired IgG tested, which
showed a 2.0-fold increase in inhibition of FXa activity
with the mixed IgG sample, whilst the four other paired
IgG showed <1.2-fold increase compared with individual
IgG (Figure 3C).The effects of anti-FXa IgG upon FXa-AT-III interactions
Having shown that anti-FXa APS-IgG had the greatest
effect upon prolongation of FXa-dependent coagulation
and enzymatic activity we then studied whether anti-FXa
inhibit AT-III mediated inactivation of FXa. In the ab-
sence of IgG, AT-III (20 nM) inhibited enzymatic activity
of FXa (2 nM) by 83.28 ± 0.27% (mean ± SEM). The re-
sults shown in Figure 4A represent the mean ± SEM of
all individual IgG from each relevant group. This inhib-
ition was significantly reduced in the presence of all in-
dividual APS-IgG but not by SLE-IgG or HC-IgG. The
mean ± SEM of all individual IgG was 62.03 ± 1.36% for
APS-IgG, 81.40 ± 0.32% for SLE-IgG and 80.16 ± 1.09%
for HC-IgG (P <0.0001 for APS versus SLE and APS ver-
sus HC). There was no significant difference between
the effects of SLE-IgG and HC-IgG (Figure 4A).
To ensure that IgG-mediated inhibition of the FXa-
AT-III interaction was not explained by binding of IgG
to AT-III we developed a novel ELISA to test serum
samples of the purified IgG used in the functional assays
for the presence of anti-AT-III IgG. Of all SLE (n = 15),
APS (n = 16) and HC (n = 9) samples tested, only four of
the APS samples showed weak binding to AT-III. APS-
IgG showed no correlation between their anti-ATIII
activity and their inhibitory effects on AT-III inactiva-
tion (r = -0.2), shown in Figure 4B for each individual
APS-IgG sample.
Discussion
Previously, we found that anti-Thr IgG in patients with
APS have high avidity and prevent AT-III inactivation of
Thr compared to those in aPL-positive patients with
SLE, who do not have APS [16]. To our knowledge this
study is the first to identify that anti-FXa (reactive) IgG
isolated from patients with APS have differential avidity
and effects upon the enzymatic and coagulant activity of
FXa compared with anti-FXa IgG isolated from patients
with SLE who do not have APS.
Several other groups have identified different anti-SP
antibodies that have been shown to inhibit the functional
activities of anticoagulant/fibrinolytic SP [7,9,12,13]. In
particular, Yang et al. reported that 5 of 38 APS patients
(13.2%) had anti-FXa IgG and found that three of six
monoclonal anti-FXa IgG significantly inhibited the inacti-
vation of FXa by AT-III [11]. In our (larger) cohort, we
found anti-FXa IgG to be significantly elevated in 20 of 59
patients (34.5%) with APS and a higher proportion (52 of
109, 49.1%) of patients with SLE who did not have APS
compared with ARD and healthy controls. Interestingly,
we also found that FXa-reactive IgG isolated from patients
with APS had significantly higher avidity and caused pro-
longation of FXa-ACT compared with SLE-IgG. FXa-ACT
is normally used to monitor the anticoagulant effect of
unfractionated heparin in patients' plasma samples and it
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Figure 3 Effect of antiphospholipid syndrome (APS) and
systemic lupus erythematosus (SLE) IgG on coagulant and
enzymatic functions of factor Xa (FXa). (A) APS and SLE IgG
significantly prolonged FXa-activated clotting time. IgG (200 μg/ml
final concentration) were incubated with FXa (3.9 nM final
concentration) for 10 minutes at 37°C followed by addition of
phospholipid, calcium and fibrinogen mixture; bars represent
mean ± standard error of the mean (SEM); P = 0.04; ****P <0.0001.
(B) APS and SLE IgG inhibit FXa activity. FXa (2 nM) was incubated
with IgG for 10 minutes at 37°C followed by the addition of
chromogenic substrate; bars, mean ± SEM; ***P = 0.0002 for SLE
versus healthy controls, P = 0.0008 for SLE versus APS; ****P <0.0001.
(C) Inhibition of FXa by individual APS or SLE IgG samples compared
to mixed APS/SLE IgG at equal final concentrations. Five APS-IgG and
SLE-IgG samples with similar FXa binding were selected and equal
concentrations mixed to compare to the ability of individual samples
to bind FXa. Inhibitions observed by individual samples and their
combinations were as follows (%): APS 1: 20.2, SLE 1: 7.1, APS 1 + SLE 1:
19.4; APS 2: 19.04, SLE 2: 17.9, APS 2 + SLE 2: 21.4; APS 3: 11.2, SLE 3:
11.4, APS 3 + SLE 3: 20.4; APS 4: 15.8, SLE 4:12.7, APS 4 + SLE 4: 19.7; APS
5: 10.4, SLE 5: 13.8, APS 5 + SLE 5: 15.2%. Experiments were performed
in duplicate for each sample. Results are representative of at least three
independent experiments.
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to subsequent fibrin clot formation [30]. This prolonga-
tion of ACT resembles an LA effect of anti-FXa IgG that
has been previously reported [31], although we did not
confirm true LA activity (with a mixing and confirmatory
step) or FXa specificity of the ACT prolongation, as IgG
directed against other clotting factors downstream of FXa
in the ACT assay may conceivably have interfered with
the results of this test.
In contrast, we did demonstrate that both APS- and
SLE-IgG directly inhibited specific FXa activity in a
chromogenic assay, but the effect was greater for APS-
IgG. Given that this activity is dependent upon cleavage
of substrate by the catalytic site of FXa, the inhibitory
effects of APS and SLE-IgG would appear to be medi-
ated through binding to this site. To examine whether
the differential effects of these IgG may be explained by
their binding to different epitopes of the FXa active site,
we compared the effects of APS-IgG, SLE-IgG and a
50/50 mix of these upon FXa activity to examine
whether an appreciable increase in ability to inhibit FXa
activity would be observed with the mixed APS/SLE-
IgG samples. Since only one of five paired samples
tested displayed a reduction in FXa activity compared to
the individual sample with the highest inhibitory acivity,
we concluded that the majority of these IgG were bind-
ing to the same epitope upon the FXa catalytic site and
that APS-IgG bind it more strongly as per our avidity
results. It is also possible that different epitopes are be-
ing recognised but that the epitope bound by SLE-IgG is
further from the catalytic site and thus, has less influ-
ence on FXa activity.
Figure 4 Factor Xa-antithrombin III (FXa-AT-III) interactions.
(A) Effect of IgG on FXa activity in the presence of AT-III (20 nM).
Bars represent the mean ± standard error of the mean of all individual
IgG from each relevant group; ****P <0.0001. (B) Inhibition of AT-III
inactivation of FXa by antiphospholipid syndrome (APS)-IgG and
AT-III binding of APS-IgG. There is no correlation of AT-III binding
of APS-IgG with inhibition of AT-III inactivation of FXa by APS-IgG.
Dots represent individual APS-IgG samples. Experiments were
performed in duplicate for each sample. Results are representative
of at least three independent experiments.
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assay demonstrated that only APS-IgG significantly re-
duced the AT-III-mediated inhibition of FXa, whereas
SLE-IgG and HC-IgG did not. AT-III is a member of the
serine protease inhibitor (serpin) family and inactivates
the enzymes responsible for the generation of Thr [32,33].
Even modest AT-III deficiency may lead to thrombosis
[32]. Previous studies by ourselves and others have shown
that aPL reduce AT-III-mediated inactivation of Thr and
FXa [9,11,16]. AT-III binds to exosite-2 on FXa which is
distinct from the catalytic site and leads to the forma-
tion of a covalent complex between the FXa active site
and a protruding reactive centre-loop (RCL) from AT-III [32,33]. This process renders FXa inactive, as it can-
not bind its substrate. As this inhibition is greatly en-
hanced by heparin, similar to the physiologic activation
of AT-III by vessel wall heparan sulfate proteoglycans,
AT-III was diluted in a buffer containing heparin. Given
that the circulating concentration of AT-III is 2 μM [33]
and that of the zymogen FX 170 nM [31], we used an
FXa-to-AT-III ratio of 1:10. We found that the effects of
APS-IgG upon the FXa-AT-III interaction were related
to binding to FXa rather than to AT-III because we did
not find a correlation between the presence of anti-AT-III
IgG and reduction of AT-III-mediated inhibition of FXa
(Figure 4B).
Overall, we suspect that this differential avidity and ef-
fects upon the enzymatic and coagulant activity of FXa
of APS compared with SLE/APS- anti-FXa IgG, occurs
through IgG binding to FXa and interference with its
functional effects upon clotting and chromogenic sub-
strates, probably by binding close to the active site, an
exosite, or some other relevant domain. The interference
with FXa inactivation by AT-III appears to be a weaker ef-
fect and may represent APS-IgG binding close to exosite-
2 upon FXa or binding elsewhere leading to structural
change, affecting this exosite. More precise epitope map-
ping and/or molecular modelling is required to clarify this
matter. It is likely that there is a balance between these
anticoagulant or procoagulant effects in vivo, which may
be different at different sites and at different times (for ex-
ample, during the development of a clot). In addition to
these effects on coagulation FXa has direct effects upon
endothelial cells mediated via protease-activated receptors
(PARs), which may also be important in the pathogenesis
of the APS. Thus, further studies of the effects of anti-FXa
IgG upon the cellular effects of FXa are required.
The presence and functional effects of anti-FXa APS-
IgG are of particular interest because new oral anticoag-
ulants such as direct FXa inhibitors are now available.
These drugs confer several advantages over current antic-
oagulation therapy with warfarin with a more predictable
anticoagulant response, little potential for food or drug in-
teractions and fixed oral dose that does not require anti-
coagulant monitoring, reviewed in [34]. In particular, a
direct FXa inhibitor (rivaroxaban) is now routinely used as
primary and secondary thromboprophylaxis in several
clinical settings and it is likely that it will be useful in
the management of patients with thrombotic APS, al-
though the presence of APS was not documented in the
relevant phase III trials.
A potential limitation of our work is the lack of age
and sex matching in healthy controls. It was impossible
however, to age match the healthy controls (mean age
31 years) with all of the different disease groups studied,
with mean ages ranging from 36 to 59 years. In fact, the
mean age of the healthy control group most closely
Artim-Esen et al. Arthritis Research & Therapy  (2015) 17:47 Page 9 of 10matches that of the disease SLE (mean 36 to 37 years)
and APS (mean 46 years) groups that were our primary
focus. With regard to the lack of sex matching in our
different groups it is notable that the highest distribution
of males (19 of 40, 47.5%) was found in the healthy con-
trol group and previous studies have found that young
males tend to have higher IgG concentrations than
females [35]. Also given the fact that none of the 21 fe-
male HC was positive for anti-FXa, it seems very un-
likely that including extra women to make the groups
sex-matched would have altered this significantly. There-
fore, we do not believe that this lack of age/sex matching
has adversely affected our results, although it will be im-
portant to avoid this discrepancy in future studies.
Not having tested IgM antibodies may be a second
limitation of our work. We have chosen to focus on IgG
antibodies in this study and in our previously published
work, because they are the best-characterised and have
the closest association with pathogenic effects in biological
assays. Other groups have also focused on IgG antibodies
and in fact we are not aware of any other studies, by our-
selves or others in this field, who have examined anti-SP
IgM. Therefore, we did not study IgM, but we think that
IgM may also play a role in some patients.Conclusions
We have shown that anti-FXa IgG isolated from patients
with APS have higher avidity to FXa and greater effects
upon the enzymatic and coagulant activity of FXa com-
pared with anti-FXa IgG isolated from patients with SLE
who lack APS. Further studies are now required to con-
firm these interesting preliminary findings in APS, SLE
and other non-autoimmune mediated VT and PM disease
cohorts. Currently, we are evaluating the pathologic, diag-
nostic and prognostic significance of anti-FXa antibodies
in these patient groups. In particular, we are examining
whether these antibodies enhance the cellular functions of
FXa, which may then enable anti-FXa IgG positivity to be
used in the management of these patients as a biomarker
for treatment with selective FXa inhibitors.
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